Dyslipoproteinemia and premature atherosclerosis in pediatric systemic lupus erythematosus

Related Experiment Videos

Laura E Schanberg1, Christy Sandborg

  • 1Division of Pediatric Rheumatology, Duke University Medical Center, Box 3212, Durham, NC 27710, USA. schan001@mc.duke.edu

Current Rheumatology Reports
|November 6, 2004
PubMed

Insights

Systemic lupus erythematosus (SLE) patients show early signs of atherosclerosis, increasing long-term cardiovascular risks. Early intervention, like statin therapy, is crucial for preventing cardiovascular disease in pediatric lupus patients.

Area of Science:

  • Pediatric Rheumatology
  • Cardiovascular Research
  • Immunology

Background:

  • Systemic lupus erythematosus (SLE) treatments improve long-term outcomes but atherosclerosis remains a significant complication.
  • Children and adolescents with SLE exhibit early dyslipoproteinemia and atherosclerosis, despite rare adult-like cardiovascular events.
  • Accelerated atherogenesis in SLE is linked to vascular, immune, inflammatory changes, and medication side effects.

Purpose of the Study:

  • To highlight the critical need for interventions targeting long-term cardiovascular disease complications in childhood lupus.
  • To emphasize the potential for significant life extension and improved quality of life through early intervention.
  • To introduce the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial as a key study in this area.

Main Methods:

  • An ongoing multi-center, randomized, controlled trial named APPLE (Atherosclerosis Prevention in Pediatric Lupus Erythematosus).
  • The trial is testing the efficacy of statins in preventing premature atherosclerosis.
  • The study population includes children and adolescents diagnosed with SLE.

Main Results:

  • Data on the efficacy of statins in preventing atherosclerosis in pediatric SLE patients is currently being gathered.
  • The APPLE trial aims to provide evidence-based guidance for future therapeutic interventions.
  • Results are expected to inform strategies for managing cardiovascular risk in this vulnerable population.

Conclusions:

  • Preventing premature atherosclerosis in pediatric SLE is a vital target for improving long-term health.
  • Statins show promise as a therapeutic intervention for mitigating cardiovascular risk in young SLE patients.
  • The findings from the APPLE trial will be instrumental in shaping future treatment guidelines for childhood lupus and cardiovascular health.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Inflammation01:38

Inflammation

Overview
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...